Results 201 to 210 of about 132,778 (287)

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

High Dihydromyricetin Loaded Biomimetic Nanoemulsion Ameliorated Early Nonalcoholic Fatty Liver Disease by Hepatic Ferroptosis Inhibition. [PDF]

Int J Nanomedicine
Yin M, Tian M, Wang W, Shi C, Fang J, Xiong W.   +5 more
europepmc   +1 more source

Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective To examine factors influencing breast cancer liver metastases (BCLM) and assess the impact of underlying liver diseases (nonalcoholic fatty liver and HBsAg infection) on BCLM development. Methods Patients diagnosed with breast cancer at four affiliated hospitals in China between 2014 and 2024 were included.
Xiaowen Wang, Yuan Zhang, Qiwei Yang, Luo Yang, Yanhui Wang, Xiangxin Zeng, Long Zou, Yujuan Guo, Wenyang Zhou, Yuqi Jiang, Jiezhong Wu, Peng Zhang, Song Zhou, Guangjuan Zheng, Tao Huang, Genshu Wang, Kunpeng Hu   +16 more
wiley   +1 more source

Impact of nonalcoholic fatty liver disease severity on community-acquired pneumonia in children and adolescents aged 6 to 17 years: A retrospective CT-based study. [PDF]

Medicine (Baltimore)
Shi H, Gu R, Tu H, Tu J, Yang G, Cao J.
europepmc   +1 more source

ChREBP refines the hepatic response to fructose to protect the liver from injury [PDF]

, 2017
Angela M. Hall, Brian N. Finck, Hetz, Montgomery   +3 more
core   +3 more sources

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source

From the Liver to Heart in Nonalcoholic Fatty Liver Disease: Single-Cell and Serum Evidence for Cytokeratin 18 in Predicting Cardiovascular Risk. [PDF]

Cardiovasc Ther
Xu H, Ma X, Chen F, Zhou B.
europepmc   +1 more source

Wernicke’s Encephalopathy Secondary to Hyperemesis Gravidarum in Pregnancy: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Wernicke's Encephalopathy, although classically associated with chronic alcoholism, can also occur during pregnancy as a complication of hyperemesis gravidarum and is often underdiagnosed. We report a case of a 34‐year‐old pregnant woman at 16 weeks of gestation who presented with prolonged vomiting, altered mental status, nystagmus, and gait ...
Abhishek Mahato, Sameer Parajuli, Bandana Ghimire, Bishal Basnet, Bishal Sigdel, Bishal Kumar Yadav, Sagar Kumar Jha   +6 more
wiley   +1 more source

Oral Icariin Nanoparticles Ameliorate Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress. [PDF]

ACS Appl Mater Interfaces
Fan S, Ma N, Li J, Wang B, Zhao Y, Yao Y, Chai X, Zhou Z.   +7 more
europepmc   +1 more source

Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This meta‐analysis compared Resmetirom and Efruxifermin in patients with MASH, focusing on improvements in key biochemical and non‐invasive markers. Efruxifermin is associated with favourable outcomes with a slightly greater effect on MRI‐PDFF and AST, along with more comparable safety outcomes.
Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh   +4 more
wiley   +1 more source